ISSN: 0975-833X

Available online at http://www.journalcra.com

International Journal of Current Research

Vol. 17, Issue, 03, pp.32142-32146, March, 2025
DOI: https://doi.org/10.24941/ijcr.48711.03.2025

INTERNATIONAL JOURNAL OF CURRENT RESEARCH

REVIEW ARTICLE

PHARMACOVIGILANCE: A GLOBAL KEY TO DRUG SAFETY MONITORING

[1]Mr. Shinde Nilesh N., [2*]Mr. Kanwate Chaitanya, G., [2]Ms. Solunke Nandini, G., [2]Mr. Mashalkar Shivshant, R. and [2]Mr. Chate Onkar K.

[1]Assistant Professor Department of Pharmaceutical chemistry at Godavari Institute of Pharmacy Kolpa, Latur-413512, Maharashtra, India; [2]Student Department of Pharmacy at Godavari Institute of Pharmacy Kolpa, Latur-413512, Maharashtra, India

ARTICLE INFO

Article History:
Received 20th December, 2024
Received in revised form
19th January, 2025
Accepted 26th February, 2025
Published online 30th March, 2025

Key words:
Drugsafety, Ericedeclaration, Pharmacovigilance.

****Corresponding author:***
Mr. Kanwate Chaitanya, G.,

ABSTRACT

Pharmacovigilance serves as a protective framework for monitoring and assessing adverse drug reactions (ADRs), playing a crucial role in drug regulatory systems, clinical practice, and public health initiatives. The increasing number of ADR reports has led to a surge in data volume, necessitating specialized expertise to promptly identify potential drug risks while ensuring that products are not unjustly withdrawn from the market. The global pharmacovigilance network, coordinated by the Uppsala Monitoring Centre, could be further enhanced by an independent review system. Such a system would focus on critical drug safety concerns that pose risks to public health beyond national borders. Traditionally, pharmacovigilance has been primarily focused on identifying previously unknown or insufficiently understood adverse drug events. As an essential component of clinical research, pharmacovigilance has been expanding worldwide. Numerous pharmacovigilance centers are actively engaged in monitoring drug safety on a global scale. However, with the advent of the new millennium, the field faces significant challenges in improving drug safety measures and monitoring practices. This review will explore drug safety, the global network of pharmacovigilance centers, their roles, advantages, challenges, and future perspectives in the healthcare sector.

Citation: Mr. Shinde Nilesh N., Mr. Kanwate Chaitanya, G., Ms. Solunke Nandini, G., Mr. Mashalkar Shivshant, R. and Mr. Chate Onkar K. 2025. "Pharmacovigilance: A Global Key to Drug Safety Monitoring*". International Journal of Current Research, 17, (03), 32142-32146.*

INTRODUCTION

The Evolving Landscape of Drug Safety and Pharmacovigilance. Drug safety and pharmacovigilance remain ever-evolving disciplines within clinical and scientific research. The World Health Organization (WHO) defines pharmacovigilance as "the science and activities related to the detection, assessment, understanding, and prevention of adverse effects or any other drug-related problem." It plays a crucial role in equipping healthcare professionals and patients with the necessary information to make informed treatment decisions.Despite their undeniable benefits, medications can also lead to significant adverse reactions, many of which are both common and preventable. In some regions, adverse drug reactions (ADRs) rank among the leading causes of morbidity and mortality. To mitigate risks and enhance public health outcomes, it is essential to establish robust monitoring and evaluation systems for drug safety. Looking ahead, pharmacovigilance is poised to undergo significant transformations over the next decade. Emerging trends such as globalization, digitalization of drug sales and information, expanded safety concerns, the balance between public health priorities and pharmaceutical industry growth, as well as the need for effective monitoring in both developed and developing nations, are shaping the future of the field. Addressing these challenges is critical to advancing pharmacovigilance and strengthening healthcare systems worldwide. This version maintains the essence of the original while improving clarity, coherence, and originality. Let me know if you'd like any further refinements

Historical perspectives on WHO Drug saftey Monitoring: By 2002, over 65 countries had established their own pharmacovigilance centers. The WHO's International Drug Monitoring program is coordinated by the Uppsala Monitoring Centre (UMC), a WHO Collaborating Centre dedicated to global drug safety. Today, pharmacovigilance is firmly rooted in scientific principles and plays a crucial role in clinical practice. However, ongoing advancements are necessary to align with public expectations and the evolving landscape of public health. The Sixteenth World Health Assembly passed Resolution WHA 16.36, emphasizing the need for swift action in disseminating information on adverse drug reactions. This resolution eventually led to the establishment of the WHO Pilot Research Project for International Drug Monitoring. The primary objective of this initiative was to create a globally applicable system for identifying previously unknown or

insufficiently understood adverse drug effects, ensuring safer medication use worldwide.

Global guardians of pharmacovigilance: Ensuring drug safety requires a collaborative effort among various stakeholders, including healthcare professionals, policymakers, researchers, and the public. These entities must work together to anticipate, understand, and address the growing expectations of health administrators, political leaders, and patients regarding medication safety.

Quality Assurance and Safety: The Quality Assurance and Safety team operates under the WHO's Department of Essential Drugs and Medicines Policy within the Health Technology and Pharmaceuticals division. Its mission is to bridge the gap between the potential benefits of essential medicines and the reality that millions—especially the disadvantaged—still face challenges such as limited availability, high costs, safety concerns, and improper use.

Uppsala Monitoring Centre (UMC): As a key player in international drug safety, the UMC maintains a global database of adverse drug reaction (ADR) reports submitted by National Pharmacovigilance Centers. It has standardized reporting protocols across countries and fosters international collaboration to rapidly identify safety signals and potential risks.

National Pharmacovigilance Centers: National Centers play a crucial role in promoting drug safety awareness. Many are housed within hospitals, medical schools, and poison control centers, rather than being solely under regulatory authorities. Advanced surveillance systems, such as prescription event monitoring (PEM) and record-linkage databases, are actively used in countries like the United Kingdom, Sweden, the United States, and New Zealand. These systems help gather epidemiological data on ADRs, and their operational costs remain minimal compared to national pharmaceutical expenditures or the economic burden of ADRs.

Hospitals and Academia: Medical institutions have implemented close monitoring systems for adverse drug reactions and medication errors within clinical settings, including wards and emergency departments. Pharmacoepidemiological methods, such as case-control studies, are extensively utilized to assess drug-related harm aftermarket release. Additionally, academic centers specializing in pharmacology and pharmacy contribute through education, training, research, clinical ethics, and policy development.

Healthcare Professionals: Initially, ADR reporting was limited to physicians, who relied on differential diagnosis to determine whether a symptom was drug-induced. Today, multiple categories of healthcare professionals are involved, each contributing unique observations on drug-related issues based on their expertise and patient interactions.

Patients' Role in Pharmacovigilance: Patients are the primary recipients of medication and the most direct witnesses to both its benefits and risks. Their active participation in reporting drug-related problems enhances pharmacovigilance efforts and compensates for the limitations of systems that rely solely on healthcare professionals' reports. Encouraging patient involvement strengthens the overall effectiveness of drug safety monitoring worldwide.

Pharmacovigilance in Drug Regulation: Pharmacovigilance programs play a crucial role in drug regulation, strengthening their effectiveness through close collaboration with regulatory authorities. Regulatory bodies recognize that pharmacovigilance is essential for maintaining the long-term safety of medicinal products.

Clinical Trial Regulation: The past decade has seen a significant rise in clinical trials across both developed and developing nations. Regulatory agencies evaluate the safety and efficacy of investigational drugs before approving clinical trials. However, monitoring the safety of medicines in widespread clinical use must also be a fundamental aspect of medical practice. Enhancing patient safety requires ongoing education and training for healthcare professionals, efficient information-sharing among national pharmacovigilance centers, and strong connections between clinical experiences, research, and health policy. A well-structured flow of information allows pharmacovigilance programs to identify knowledge gaps related to medicine-induced diseases.

Post-Marketing Drug Safety Monitoring: Post-marketing surveillance involves detecting drug interactions, evaluating the environmental impact of medications used by large populations, and assessing the role of inactive ingredients in drug safety. Additionally, it includes comparative safety analyses of similar drugs and monitoring the potential health effects of drug residues in animals, such as antibiotics and hormones. The Council for International Organizations of Medical Sciences (CIOMS) has contributed to improving benefit-risk assessment methods for medicines after they reach the market, leading to a more structured approach to evaluating their overall impact.

Pharmacovigilance in National Drug Policy: Ensuring the availability of high-quality, safe, and effective medicines—and promoting their responsible use—is a key responsibility of national governments. Multidisciplinary collaboration is essential, particularly between health ministries, pharmaceutical companies, universities, NGOs, and professional organizations focused on rational drug use and pharmacotherapy monitoring. Strong partnerships across these sectors help reinforce national drug policies and improve medication safety.

Pharmacovigilance in Public Health and Disease Control Programs: Monitoring the safety of medicines is particularly challenging in regions lacking regulatory frameworks or healthcare infrastructure. This issue is especially critical in the treatment of diseases such as malaria, schistosomiasis, leishmaniasis, tuberculosis, and HIV/AIDS, which often require mass drug administration in remote or underserved areas. Effective pharmacovigilance should be a priority for all countries with public health disease control programs to ensure the safe and effective use of medicines, even in the most challenging healthcare environments.

Pharmacovigilance and Global Health: The worldwide network of pharmacovigilance centers, coordinated by the Uppsala Monitoring Centre, could be further strengthened through an independent review system. Such a system would focus on evaluating critical drug safety concerns that extend

beyond national borders and pose potential risks to public health. The Erice Declaration outlines ethical principles and best practices for the collection, analysis, and transparent communication of drug safety information. Despite significant advancements in pharmacovigilance, adverse drug reactions (ADRs) continue to place a substantial burden on global healthcare systems. Pharmacoeconomic research highlights the considerable financial strain ADRs impose on healthcare budgets, with governments allocating substantial funds to manage their consequences. However, medication safety is not solely a scientific or regulatory issue—it is also influenced by socio-political, economic, and cultural factors. These elements shape public perceptions, access to medicines, and patterns of drug utilization, all of which impact overall drug safety.

Drug Utilization and Its Impact on Safety: Patterns of drug use play a crucial role in determining medication safety. For example, injectable medications are more frequently used in developing countries. Additionally, direct-to-consumer advertising of prescription drugs has become widespread in certain regions, empowering patients to make their own treatment decisions—sometimes without consulting a doctor or pharmacist. This trend has led to a rise in self-medication, unregulated online sales of medicines, and increased prescribing by physicians in response to patient demands. Such practices can significantly affect drug safety and contribute to inappropriate medication use. Public health initiatives should not only target individual patients but also focus on educating the broader population, including children and the elderly. Collaborative efforts involving media organizations, educational institutions, governmental bodies, and non-governmental organizations can enhance public awareness of safe medicine use. The success of WHO's International Drug Monitoring Program depends heavily on the active participation of national pharmacovigilance centers. Ideally, every country should establish a dedicated pharmacovigilance center to ensure robust monitoring and reporting systems, ultimately strengthening global drug safety efforts.

Pandemic Pharmacovigilance Update: News Broadcast The overall benefit-risk assessment of pandemic vaccines and antiviral treatments for the H1N1 influenza outbreak remains favorable. So far, no unexpected serious safety concerns have emerged. Reported adverse reactions have been largely mild and in line with anticipated effects. In November 2009, the European Medicines Agency (EMEA) reaffirmed the effectiveness and safety of centrally authorized vaccines through an official statement. With vaccination campaigns actively progressing across the European Union, approximately 10 million individuals had received the vaccine at that time. The most commonly reported side effects included fever, nausea, headaches, allergic reactions, and localized injection site reactions—consistent with the expected safety profile of the three authorized vaccines. Additionally, new clinical trial data indicated a higher incidence of fever following the second dose of the Pandemrix vaccine in infants aged 6 to 35 months. Regulatory bodies are currently assessing this data to ensure continued vaccine safety monitoring.

Future Considerations and Challenges in Pharmacovigilance: Over the next decade, pharmacovigilance programs will face significant challenges, shaping the evolution of drug safety monitoring. Addressing these challenges requires strategic improvements to enhance pharmacovigilance practices and ensure a stronger foundation for patient safety.

Key Areas for Improvement in Pharmacovigilance

- **Shifting Focus from Harm to Safety Knowledge –** Instead of primarily identifying adverse effects, pharmacovigilance should also emphasize expanding knowledge about medication safety.
- **Utilizing Formal Decision Analysis –** Complex risk-benefit evaluations can be enhanced through structured decision-making frameworks, leading to more informed regulatory and clinical decisions.
- **Encouraging Scientific Advancement –** Pharmacovigilance should be grounded in scientific research, requiring interdisciplinary collaboration, robust academic support, and better training opportunities.
- **Implementing Standardized Audits –** A systematic approach to evaluating pharmacovigilance processes should be adopted based on internationally accepted guidelines for good pharmacovigilance practices (GVP).

Major Challenges in Pharmacovigilance

Globalization of Drug Distribution – The widespread distribution of medications, including novel therapeutic agents and essential drugs for diseases like HIV/AIDS, malaria, and tuberculosis, has increased the scale and complexity of safety monitoring. Online Drug Sales and Information – The internet has facilitated the unregulated sale of pharmaceuticals across borders, including prescription drugs, unregistered medicines, and controlled substances. The widespread availability of misleading or incomplete drug information online poses serious safety risks.

Expanding Scope of Drug Safety Concerns – Pharmacovigilance now extends beyond adverse drug reactions (ADRs) to encompass issues such as medication errors, drug interactions, polypharmacy, substandard medicines, self-medication, and the combined use of traditional and modern medicines. Existing monitoring systems must evolve to address these broader concerns effectively. Balancing Public Health and Pharmaceutical Industry Growth – There are often conflicts between public health priorities and the commercial interests of pharmaceutical companies. The industry must improve its approach to safety monitoring in both clinical trials and post-marketing surveillance. Ongoing Monitoring of Established Medications – Generic drug manufacturers must take greater responsibility for monitoring the safety of their products globally. There is a misconception that generic medicines are inherently safe, even though they may interact with other drugs. Since generic drugs make up a significant portion of essential medicines, ongoing surveillance is crucial.

Public Perception of Benefits and Risks – The way patients, healthcare providers, and the general public perceive medication safety has shifted dramatically. However, these perceptions have not been adequately considered in drug regulation. The impact of drug-induced diseases is increasingly recognized as a major public health issue. Impact and Accountability in Pharmacovigilance – With rising public awareness, there is greater scrutiny on healthcare professionals, regulatory agencies, and pharmaceutical companies regarding drug safety. Increased transparency and accountability should drive further research into the effectiveness of pharmacovigilance systems. A key priority is to empower healthcare providers and patients with reliable information to improve treatment decisions, reduce medication-related

illnesses, and enhance overall drug safety. Addressing these challenges will be crucial in shaping the future of pharmacovigilance, ensuring that drug safety monitoring continues to evolve alongside advancements in medicine and public health needs.

CONCLUSION

Pharmacovigilance plays a vital role in addressing the challenges posed by the expanding variety and potency of medicines, each of which carries an inherent, sometimes unpredictable, risk of harm. When adverse effects or toxicity arise, especially when they were previously unknown, it is critical to report, analyze, and communicate these findings clearly to stakeholders who can interpret and act on the information. For all medications, there is an inevitable trade-off between their benefits and potential risks. The impact of harm can be minimized by ensuring the rational use of safe, effective, and high-quality medicines, while considering patient concerns and expectations when making therapeutic decisions.

Ultimately, the goal of pharmacovigilance is to protect public health, build trust between patients and healthcare systems, anticipate and manage medication risks, and provide regulators with the information necessary to refine safety guidelines. It also emphasizes improving communication between healthcare professionals and the public, and fostering education for healthcare providers on the benefits and risks associated with the medicines they prescribe. This ensures better-informed decisions, promoting overall patient safety and confidence in healthcare systems.

ACKNOWLEDGEMENT

The author thanks prof. Shinde Nilesh N. Assistance Professor, Department of pharmaceutical chemistry, Godavari Institute of Pharmacy Kolpa, Latur, (M.S.) India. For helpful discussion.

REFERENCES

Pharmacovigilance WH. Ensuring the safe use of medicines. WHO policy perspective of medicine, WHO, Geneva. 2004.

Härmark L, van Grootheest A. Pharmacovigilance: methods, recent developments and future perspectives. European journal of clinical pharmacology. 2008 Aug;64:743-52.

Biswas P, Biswas AK. Setting standards for proactive pharmacovigilance in India: The way forward. Indian journal of pharmacology. 2007 May 1;39(3):124-8.

The Importance of pharmacovigilance Safety monitoring of medicinal products. WHO Lib Catalog. 2002. Available from: http://www.apps.who. int/medicinedocs/en/d/Js4893e/. [last cited on 2009 Dec 25].

World Health Organization, Board E, editors. Handbook of Resolutions and Decisions of the World Health Assembly and the Executive Board: 1948/1972. World Health Organization; 1973.

Lared NL. Pharmacists' role in reporting adverse drug reactions in an international perspective. 2003. Available from: http://www.lareb.nl/ documents/pds2004_1291.pdf. [last cited on 2010 Jan 28].

World Health Organization. WHO medicines strategy: framework for action in essential drugs and medicines policy 2000-2003.

Olsson S. The role of the WHO programme on International Drug Monitoring in coordinating worldwide drug safety efforts. Drug safety. 1998 Jul;19(1):1-0.

Coulter DM. The New Zealand intensive medicines monitoring programme in pro-active safety surveillance. Pharmacoepidemiology and drug safety. 2000 Jul;9(4):273-80.

Mackay FJ. Post-marketing studies: the work of the Drug Safety Research Unit. Drug safety. 1998 Nov;19(5):343-53.

Folb PI. Drug monitoring in developing countries: a drug regulator's perspective. Drug information journal. 1995 Jan;29(1):303-5.

Talbot JC, Nilsson BS. Pharmacovigilance in the pharmaceutical industry. British journal of clinical pharmacology. 1998 May;45(5):427.

Moore N. The role of the clinical pharmacologist in the management of adverse drug reactions. Drug Safety. 2001 Jan;24:1-7.

Hall M, McCormack P, Arthurs N, Feely J. The spontaneous reporting of adverse drug reactions by nurses. British journal of clinical pharmacology. 1995 Aug;40(2):173-5.

Hornbuckle K, Wu HH, Fung MC. Evaluation of spontaneous adverse event reports by primary reporter—a 15-year review (1983 to 1997). Drug information journal: DIJ/Drug Information Association. 1999 Oct;33(4):1117-24.

Council for International Organizations of Medical Sciences. Benefit-risk balance for marketed drugs: evaluating safety signals: report of CIOMS Working Group IV. (No Title). 1998.

Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. Jama. 1998 Apr 15;279(15):1200-5.

White TJ, Arakelian A, Rho JP. Counting the costs of drug-related adverse events. Pharmacoeconomics. 1999 May;15:445-58.

Avorn J, Solomon DH. Cultural and economic factors that (mis) shape antibiotic use: the nonpharmacologic basis of therapeutics. Annals of internal medicine. 2000 Jul 18;133(2):128-35.

Ball LK, Evans G, Bostrom A. Risky business: challenges in vaccine risk communication. Pediatrics. 1998 Mar 1;101(3):453-8.

Bapna JS, Tripathi CD, Tekur U. Drug utilisation patterns in the Third World. Pharmacoeconomics. 1996 Apr;9:286-94.

Kane A, Lloyd J, Zaffran M, Simonsen L, Kane M. Transmission of hepatitis B, hepatitis C and human immunodeficiency viruses through unsafe injections in the developing world: model-based regional estimates. Bulletin of the World Health Organization. 1999;77(10):801.

de Vries CS, Duggan CA, Tromp TF, de Jong-van den Berg LT. Changing prescribing in the light of tolerability concerns: How is this best achieved?. Drug safety. 1999 Sep;21:153-60.

Sleath B, Svarstad B, Roter D. Physician vs patient initiation of psychotropic prescribing in primary care settings: A content analysis of audiotapes. Social science & medicine. 1997 Feb 1;44(4):541-8.

Offit PA, DeStefano F. Vaccine safety. Vaccines. 2012 Nov 7:1464.

Jeetu G, Anusha G. Pharmacovigilance: a worldwide master key for drug safety monitoring. Journal of Young Pharmacists. 2010 Jul 1;2(3):315-20.

Bowdler J. Effective communications in pharmacovigilance: the Erice report. Birmingham: W Lake. 1997.

Ioannidis JP, Lau J. Completeness of safety reporting in randomized trials: an evaluation of 7 medical areas. Jama. 2001 Jan 24;285(4):437-43.

Waller PC, Wood SM, Langman MJ, Breckenridge AM, Rawlins MD. Review of company postmarketing surveillance studies. British Medical Journal. 1992 Jun 6;304(6840):1470-2.

****